Mural Oncology

Focus: Mural Oncology is a Waltham, MA-based immunotherapy biotech focused on oncology with a pipeline of early-stage programs targeting advanced solid tumors and hematologic malignancies. The company operates as a pre-revenue stage biotech with multiple clinical-stage assets in development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Mural Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow Mural Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ALKS 4230

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT03861793A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Phase 1/2

Help build intelligence for Mural Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline includes Phase 3 combination trial (Nemvaleukin + Pembrolizumab in platinum-resistant ovarian cancer), offering near-term catalysts and clinical validation opportunity
Focused immunotherapy approach in oncology with multiple shots on goal across solid tumors and melanoma—growing clinical evidence base across 5 active trials
Early-stage biotech environment in Boston biotech hub offers mentorship, broad exposure, and equity upside potential for individual contributors

Watch Out For

Zero current open positions (activeJobCount: 0) indicates company is not actively hiring or may be in cash-conservation mode
Pre-revenue stage with no disclosed funding, financials, or employee count raises material uncertainty on cash runway, burn rate, and job security
All programs remain early-phase (highest is Phase 3, but no marketed products); no near-term revenue generation or commercial infrastructure building

Generated by Claude from Mural Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ALKS 4230

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT02799095A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Phase 1/2

Nemvaleukin alfa

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT04592653Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Phase 1/2

Nemvaleukin Alfa

Squamous Cell Carcinoma of Head and Neck

Phase 2

Clinical Trials (1)

NCT04144517A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Phase 2

Nemvaleukin Alfa Subcutaneous

Cutaneous Melanoma

Phase 2

Clinical Trials (1)

NCT04830124Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6